301301 川宁生物
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入3,435,984-22.90%5,758,3084,823,3353,820,6583,232,015
减:营业总成本2,650,558-15.98%4,059,7563,648,8303,242,0793,005,252
    其中:营业成本2,308,977-19.27%3,663,0923,300,3972,873,2162,514,089
               财务费用25,404-40.17%48,35660,831123,008177,767
               资产减值损失(23,133)173.62%(17,074)(42,651)(16,556)(12,639)
公允价值变动收益(226)-135.13%32(1,184)(58)548
投资收益(2,025)-71.71%(9,195)(13,551)(8,902)3,337
    其中:对联营企业和合营企业的投资收益(2,333)538.58%(779)(146)(71)0
营业利润767,936-40.69%1,687,7631,121,400545,121223,625
利润总额751,775-41.17%1,675,0921,117,711487,632134,081
减:所得税费用140,871-30.25%274,742177,14676,11422,734
净利润610,904-43.22%1,400,350940,565411,517111,347
减:非控股权益(489)-1,369.10%261(1)0
股东净利润611,393-43.17%1,400,324940,564411,518111,347

市场价值指针
每股收益 (元) *0.270-43.75%0.6300.4200.2100.060
每股派息 (元) *----0.2700.2250.093--
每股净资产 (元) *3.5544.56%3.5463.1312.7912.386
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容